132 related articles for article (PubMed ID: 17685740)
1. Cost-efficacy of individual and combined treatments for panic disorder.
McHugh RK; Otto MW; Barlow DH; Gorman JM; Shear MK; Woods SW
J Clin Psychiatry; 2007 Jul; 68(7):1038-44. PubMed ID: 17685740
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of psychological and pharmacological interventions for generalized anxiety disorder and panic disorder.
Heuzenroeder L; Donnelly M; Haby MM; Mihalopoulos C; Rossell R; Carter R; Andrews G; Vos T
Aust N Z J Psychiatry; 2004 Aug; 38(8):602-12. PubMed ID: 15298582
[TBL] [Abstract][Full Text] [Related]
3. Cognitive-behavioral therapy, imipramine, or their combination for panic disorder: A randomized controlled trial.
Barlow DH; Gorman JM; Shear MK; Woods SW
JAMA; 2000 May; 283(19):2529-36. PubMed ID: 10815116
[TBL] [Abstract][Full Text] [Related]
4. Direct cost of depression: analysis of treatment costs of paroxetine versus Imipramine in Canada.
Lapierre Y; Bentkover J; Schainbaum S; Manners S
Can J Psychiatry; 1995 Sep; 40(7):370-7. PubMed ID: 8548716
[TBL] [Abstract][Full Text] [Related]
5. Economics of treatment of depression.
Owens DW
Br J Psychiatry; 1995 Jul; 167(1):112. PubMed ID: 7551591
[No Abstract] [Full Text] [Related]
6. Cost analysis of paroxetine versus imipramine in major depression.
Bentkover JD; Feighner JP
Pharmacoeconomics; 1995 Sep; 8(3):223-32. PubMed ID: 10155618
[TBL] [Abstract][Full Text] [Related]
7. Economic evaluation of paroxetine and imipramine in depressed outpatients.
Melton ST; Kirkwood CK; Farrar TW; Brink DD; Carroll NV
Psychopharmacol Bull; 1997; 33(1):93-100. PubMed ID: 9133757
[TBL] [Abstract][Full Text] [Related]
8. Incremental cost-effectiveness of pharmacotherapy and two brief cognitive-behavioral therapies compared with usual care for panic disorder and noncardiac chest pain.
Poirier-Bisson J; Marchand A; Pelland ME; Lessard MJ; Dupuis G; Fleet R; Roberge P
J Nerv Ment Dis; 2013 Sep; 201(9):753-9. PubMed ID: 23995030
[TBL] [Abstract][Full Text] [Related]
9. Treatment of panic disorder with agoraphobia: randomized placebo-controlled trial of four psychosocial treatments combined with imipramine or placebo.
Marchand A; Coutu MF; Dupuis G; Fleet R; Borgeat F; Todorov C; Mainguy N
Cogn Behav Ther; 2008; 37(3):146-59. PubMed ID: 18608313
[TBL] [Abstract][Full Text] [Related]
10. Preliminary evidence for cognitive mediation during cognitive-behavioral therapy of panic disorder.
Hofmann SG; Meuret AE; Rosenfield D; Suvak MK; Barlow DH; Gorman JM; Shear MK; Woods SW
J Consult Clin Psychol; 2007 Jun; 75(3):374-9. PubMed ID: 17563154
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of CBT, SSRI, and CBT+SSRI in the treatment for panic disorder.
van Apeldoorn FJ; Stant AD; van Hout WJ; Mersch PP; den Boer JA
Acta Psychiatr Scand; 2014 Apr; 129(4):286-95. PubMed ID: 23834587
[TBL] [Abstract][Full Text] [Related]
12. A comparison of medication side effect reports by panic disorder patients with and without concomitant cognitive behavior therapy.
Marcus SM; Gorman J; Shear MK; Lewin D; Martinez J; Ray S; Goetz R; Mosovich S; Gorman L; Barlow D; Woods S
Am J Psychiatry; 2007 Feb; 164(2):273-5. PubMed ID: 17267790
[TBL] [Abstract][Full Text] [Related]
13. Treatment of panic disorder: focus on paroxetine.
Pollack MH; Doyle AC
Psychopharmacol Bull; 2003; 37 Suppl 1():53-63. PubMed ID: 14566201
[TBL] [Abstract][Full Text] [Related]
14. Fluoxetine and imipramine: are there differences in cost-utility for depression in primary care?
Serrano-Blanco A; Suárez D; Pinto-Meza A; Peñarrubia MT; Haro JM;
J Eval Clin Pract; 2009 Feb; 15(1):195-203. PubMed ID: 19239602
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of evidence-based pharmacotherapy or cognitive behavior therapy compared with community referral for major depression in predominantly low-income minority women.
Revicki DA; Siddique J; Frank L; Chung JY; Green BL; Krupnick J; Prasad M; Miranda J
Arch Gen Psychiatry; 2005 Aug; 62(8):868-75. PubMed ID: 16061764
[TBL] [Abstract][Full Text] [Related]
16. The effects of tianeptine or paroxetine on 35% CO2 provoked panic in panic disorder.
Schruers K; Griez E
J Psychopharmacol; 2004 Dec; 18(4):553-8. PubMed ID: 15582922
[TBL] [Abstract][Full Text] [Related]
17. Empirically supported treatments for panic disorder: costs, benefits, and stepped care.
Otto MW; Pollack MH; Maki KM
J Consult Clin Psychol; 2000 Aug; 68(4):556-63. PubMed ID: 10965630
[TBL] [Abstract][Full Text] [Related]
18. Economic analysis of treating depression with nefazodone v. imipramine.
Montgomery SA; Brown RE; Clark M
Br J Psychiatry; 1996 Jun; 168(6):768-71. PubMed ID: 8773822
[TBL] [Abstract][Full Text] [Related]
19. Efficacy studies of paroxetine in panic disorder.
Lydiard RB; Steiner M; Burnham D; Gergel I
Psychopharmacol Bull; 1998; 34(2):175-82. PubMed ID: 9640997
[TBL] [Abstract][Full Text] [Related]
20. Treatment of panic disorder in older adults: a pilot study comparison of alprazolam, imipramine, and placebo.
Sheikh JI; Swales PJ
Int J Psychiatry Med; 1999; 29(1):107-17. PubMed ID: 10376237
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
